Dual effect of IL-4 on resistance to systemic gram-negative infection and production of TNF-alpha.
To determine the effect of interleukin 4 (IL-4) administration in a live sepsis model characterised by high-level production of tumour necrosis factor a (TNF-alpha), mice infected systemically with lethal or sublethal inocula of Pseudomonas aeruginosa were given the recombinant cytokine at different times before infection. Improved survival and decreased TNF-alpha production were observed in lethally infected mice treated with the cytokine 1 day before challenge. In contrast, increased mortality and overproduction of TNF-alpha were observed in sublethally infected mice given IL-4 at the time of infection.
Giampietri
A
A
Department of Experimental Medicine, University of Perugia, Italy.
Grohmann
U
U
Vacca
C
C
Fioretti
M C
MC
Puccetti
P
P
Campanile
F
F
D000818:Animals; D002478:Cells, Cultured; D004195:Disease Models, Animal; D018664:Interleukin-12 / Q000276:immunology / Q000494:pharmacology; D015847:Interleukin-4 / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000276:immunology / Q000494:pharmacology; D008264:Macrophages / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D051379:Mice; D011552:Pseudomonas Infections / Q000276:immunology* / Q000517:prevention & control; D011550:Pseudomonas aeruginosa; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000378:metabolism; D018805:Sepsis / Q000276:immunology* / Q000517:prevention & control; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D018664:Interleukin-12; D015847:Interleukin-4